Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.79 |
| ▸ | GSK3A | P49840 | 12/20 | 0.79 |
| ▸ | AURKA | O14965 | 8/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | BLK | P51451 | 1/20 | 0.48 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763823 | 0.90 | GSK3A (0.62) | GSK3BGSK3AAURKAEGFRFLT3 | |
| SCHEMBL13763922 | 0.88 | GSK3B (1.00) | GSK3BGSK3AAURKA | |
| SCHEMBL13763924 | 0.88 | GSK3B (0.79) | GSK3BGSK3AAURKAEIF2AK4 | |
| SCHEMBL3424044 | 0.88 | GSK3B (0.79) | GSK3BGSK3AAURKAEGFREIF2AK4 | |
| SCHEMBL8297919 | 0.88 | GSK3A (0.69) | GSK3BGSK3AAURKAEGFRFLT3 | |
| SCHEMBL13764067 | 0.87 | AURKA (0.65) | GSK3BGSK3AAURKAEGFRFLT3 | |
| SCHEMBL13764025 | 0.86 | GSK3B (0.76) | GSK3BGSK3AAURKAEGFRFLT3 | |
| SCHEMBL13764026 | 0.86 | GSK3B (0.69) | GSK3BGSK3AAURKAMAPK8MAPK10 | |
| SCHEMBL13949717 | 0.86 | GSK3A (0.63) | GSK3BGSK3AAURKAEGFRFLT3 | |
| SCHEMBL13764033 | 0.85 | GSK3B (0.73) | GSK3BGSK3AAURKAEIF2AK4PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560458-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-14 | — | — | US | disclosed |
| US-7560458-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-14 | — | — | US | disclosed |
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | EDGARD EDDY JEAN | 2009-02-05 | — | — | US | disclosed |
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | EDGARD EDDY JEAN | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | GSK3B, GSK3A, GYS2 | GSK3B 1/4885GSK3A 2/4885AURKA 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.